Conduit Pharmaceuticals Faces Critical Juncture After Pivot to Biotech

Conduit Pharmaceuticals, after pivoting from real estate to biotech, struggles with a $7.5M market cap and Nasdaq compliance issues, forcing a reverse stock split to avoid delisting.

The bold transition from a real estate-focused special purpose acquisition company (SPAC) to a biopharmaceutical firm has yet to yield the desired turnaround for Conduit Pharmaceuticals. With a market capitalization standing at just $7.5 million and a precarious financial position, the company is confronting significant obstacles. Investors are now closely monitoring management's efforts to avert a potential delisting from the Nasdaq exchange.

A Drastic Strategic Shift

Originally launched in 2021 as Murphy Canyon Acquisition, the entity began as a classic blank-check company targeting opportunities in the real estate sector. Its initial public offering in 2022 raised approximately $132 million. However, a strategic reversal followed. In September 2023, the company finalized a merger with Conduit Pharmaceuticals, completely shifting its operational focus to the development of clinical-stage drug candidates. Since that transaction, its equity has traded on the Nasdaq under the ticker symbol "CDT."

Financial Distress and Exchange Compliance Challenges

Despite this strategic realignment and the licensing of compounds from pharmaceutical giant AstraZeneca, the company's situation has recently deteriorated. The stock hit a new 52-week low in January 2025. Financial analysts assess the firm's economic health as weak. A particularly pressing issue is its non-compliance with the Nasdaq's minimum bid price requirement.

To prevent removal from the exchange, shareholders have already approved a reverse stock split. This maneuver is designed to artificially boost the share price, though the market frequently interprets such actions as a sign of underlying strain. Concurrently, the company secured approval to issue new shares related to option exercises and the conversion of promissory notes.

The immediate priority is stabilizing the balance sheet and advancing the drug pipeline. The critical question remains whether the planned capital measures and forthcoming clinical data from the licensed compounds will be sufficient to secure the Nasdaq listing over the long term and rebuild confidence among capital market participants.